Related Experiment Video
Updated: Jul 17, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free
Anthony H-C Choi1, Kristi Smiley, Mitali Basu
1Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. anthony.choi@cchmc.org
Abstract:
Mucosal administration (intranasal or oral) of a VP6 rotavirus vaccine to mice consistently elicits high levels of protection after rotavirus challenge (93->99% reductions in fecal rotavirus shedding) but only when co-administered with an effective adjuvant such as LT(R192G). Here, we showed that Biojector needle-free injection of VP6-encoded plasmids also induced protection (85-93%) when they were co-administrated with LT(R192G)-encoded plasmids. A reduction in the amount of VP6 plasmid from 50 to 10 microg reduced protection from 93 to 70%, but the immunized mice remained significantly (P<0.05) protected. Intramuscular needle injection of VP6/LT(R192G)-plasmids also induced significant protection (66%).
